Journal article
Group A streptococcal vaccines: Paving a path for accelerated development
James B Dale, Vincent A Fischetti, Jonathan R Carapetis, Andrew C Steer, Samba Sow, Rajesh Kumar, Bongani M Mayosi, Fran A Rubin, Kim Mulholland, Joachim Maria Hombach, Florian Schoedel, Ana Maria Henao-Restrepo
VACCINE | ELSEVIER SCI LTD | Published : 2013
Abstract
Group A streptococci (GAS) are important causes of morbidity and mortality worldwide. These organisms cause a wide spectrum of disease, ranging from uncomplicated sore throat to invasive, life-threatening infections, as well as immune complications such as acute rheumatic fever (ARF), rheumatic heart disease (RHD) and acute post-streptococcal glomerulonephritis (APSGN). Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades. Several vaccine candidates against GAS infection are in various stages of pre-clinical and clinical development, including M protein-based vaccines (N-terminal vaccine candidates and M protein conserved regio..
View full abstractGrants
Funding Acknowledgements
Funding to support this collaborative was provided by the Decade of Vaccines Consultancy and the World Health Organization's Initiative for Vaccine Research. Altaf Lal of the Decade of Vaccines provided thoughtful guidance and comments during the preparation of the manuscript.